Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide +/- Cabergoline in Cushing's Disease
NCT01915303Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2014
- Primary completion
- Sep 2016
- Modality
- Peptides, Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of pasireotide LAR in Cushing's disease (CD), sponsored by Novartis. Started Mar 2014; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT01915303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01915303.